Providence Therapeutics Holdings Inc.
$8,660,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2021-2022
- Agreement period
- July 23, 2021 – November 30, 2022
- Reference
- nrc-cnrc:172-2021-2022-Q2-976618
Published purpose
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
In plain English AI-generated
Funding supports Providence Therapeutics in conducting a Phase II clinical trial for a Canadian-made COVID-19 mRNA vaccine and developing vaccines targeting variants of concern.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.